Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer

Despite advancements in treatment options, the overall cure and survival rates for non-small cell lung cancers (NSCLC) remain low. While small-molecule inhibitors of epigenetic regulators have recently emerged as promising cancer therapeutics, their application in patients with NSCLC is limited. To...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Li, Fei, Ng, Wai-Lung, Luster, Troy A., Hu, Hai, Sviderskiy, Vladislav O., Dowling, Catríona M., Hollinshead, Kate E.R., Zouitine, Paula, Zhang, Hua, Huang, Qingyuan, Ranieri, Michela, Wang, Wei, Fang, Zhaoyuan, Chen, Ting, Deng, Jiehui, Zhao, Kai, So, Hon-Cheong, Khodadadi-Jamayran, Alireza, Xu, Mousheng, Karatza, Angeliki, Pyon, Val, Li, Shuai, Pan, Yuanwang, Labbe, Kristen, Almonte, Christina, Poirier, John T., Miller, George, Possemato, Richard, Qi, Jun, Wong, Kwok-Kin
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7493834/
https://ncbi.nlm.nih.gov/pubmed/32646968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-3782
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados